Polymyxin Results Timeline: What Studies Measured, and When

Polymyxins, chiefly polymyxin B and colistin (polymyxin E), are membrane-targeting lipopeptide antibiotics that returned to clinical use as last-resort agents against multidrug-resistant Gram-negative bacteria, as described in a 2022 review of polymyxin and lipopeptide antibiotics (PMID 35118938). Because they are hospital antibiotics and not self-directed compounds, the question of "how long until results" is answered in the literature only as what endpoint was measured, in whom, and at which timepoint. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about infection, antibiotics or treatment.

What "Results" Means in the Polymyxin Literature

Across the published record, "results" refers to pre-specified measurements, not to subjective improvement. Four broad categories recur:

• Laboratory killing kinetics, bacterial counts measured over hours in vitro, discussed in a 2021 pharmacological review of the last-line polymyxins (PMID 33627412).
• Pharmacokinetic sampling, plasma concentrations measured after dosing, a central theme of that same 2021 review (PMID 33627412).
• Clinical and microbiological endpoints, cure, eradication, and survival assessed over days to weeks, pooled in a 2019 meta-analysis of polymyxin use in patients (PMID 31364077).
• Fixed-day mortality endpoints, most prominently 28-day mortality, the primary endpoint of the EUPHRATES randomised clinical trial of targeted polymyxin B haemoperfusion in septic shock with elevated endotoxin level (PMID 30304428).

Timeline Table: Measurement Windows Reported in the Literature

Hours: Mechanism and Pharmacokinetic Sampling

The earliest measurable events in the polymyxin literature are not clinical at all. A 2022 microbiology review described polymyxins and related lipopeptides as membrane-targeting drugs of last resort, framing their activity around interaction with the Gram-negative outer membrane (PMID 35118938). That is in-vitro and mechanistic work, not a patient timeline, and researchers did not present it as a prediction of how quickly any individual improves.

The 2021 pharmacological review titled around rescuing the last-line polymyxins placed pharmacokinetics and pharmacodynamics at the centre of its account of achievements and remaining challenges, including the difficulty of optimising exposure (PMID 33627412). In practical terms, the measurement window there was hours: plasma concentration profiles after administration, and the relationship between those exposures and bacterial response. No single dose is reproduced on this page, because the verified source set reports these as review-level pharmacology rather than a protocol.

Why combination questions sit in the same early window

Two 2019 reviews asked whether polymyxins should be used alone or with partner agents: one posed the question directly as "to combine or not to combine" (PMID 30974813), and the other examined rational combinations of polymyxins with other antibiotics (PMID 31364082). These reviews addressed decisions made at or near the start of therapy, which is why combination evidence belongs to the earliest part of any results timeline rather than to a later follow-up visit.

Days: The In-Hospital Measurement Window

Once polymyxins are given systemically, the measurements that follow are made over days of hospital care. A 2019 review of the clinical use of polymyxin B surveyed how the drug was used in patients and what clinicians monitored during that course (PMID 31364080). A companion 2019 meta-analysis of polymyxin use in patients pooled outcome data across studies rather than following a single cohort over time (PMID 31364077).

Pooled analyses of this kind compress many different follow-up schedules into one summary estimate. That is a limitation worth keeping in view: a reader cannot extract "day 3" or "day 7" expectations from a meta-analysis that aggregated studies with differing definitions of cure, differing pathogens and differing durations, as the 2019 meta-analysis of polymyxin use in patients illustrates (PMID 31364077).

Day 28: The Anchor Point in Sepsis Trials

The clearest fixed timepoint in the modern polymyxin literature is day 28. The EUPHRATES randomised clinical trial, published in JAMA in 2018, tested targeted polymyxin B haemoperfusion in patients with septic shock and elevated endotoxin level, and its stated endpoint was 28-day mortality (PMID 30304428). The study did not report a mortality benefit at that timepoint in the trial population it randomised (PMID 30304428).

More recently, the Tigris trial was published as a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial of polymyxin B haemoadsorption in endotoxic septic shock (PMID 41887242). Its Bayesian design means that the probability statements researchers reported are interpreted differently from conventional p-values, which matters when comparing it with earlier frequentist trials such as EUPHRATES (PMID 30304428).

At the evidence-synthesis level, a 2023 network meta-analysis in Critical Care Medicine compared blood purification strategies for adults with severe infection or sepsis and septic shock, drawing on randomised controlled trials (PMID 37470680). Network meta-analyses of this type sit downstream of the individual trials and inherit whatever follow-up windows those trials used, including the 28-day convention used in EUPHRATES (PMID 30304428).

Why two patients with the same diagnosis may not track the same way

A 2026 study in the Journal of Clinical Investigation reported that pathogen characteristics were key determinants of distinct host response phenotypes of sepsis (PMID 41837287). That finding is relevant to any timeline discussion: if the host response differs systematically by pathogen, then averaged trial timelines describe populations rather than individuals, and the 28-day endpoint used in trials such as EUPHRATES captures only one slice of a heterogeneous process (PMID 30304428).

Weeks: The Topical Ear Literature

A different timeline appears in the topical setting. A 2020 Cochrane systematic review examined topical antibiotics for chronic suppurative otitis media, a field in which polymyxin B has long appeared as a component of combination ear preparations (PMID 31896168). The review organised its outcome assessments around resolution of ear discharge measured in defined windows, broadly at around one to two weeks, at two to four weeks, and after four weeks (PMID 31896168).

Those windows are a useful illustration of how review authors impose structure on a scattered literature: trials that measured at slightly different days were grouped so they could be compared, and the Cochrane authors reported certainty-of-evidence judgements alongside the pooled estimates (PMID 31896168). The page does not restate effect sizes from that review, because the comparisons involved multiple drug classes and the relevant point here is the timing of measurement, not a claim about any single preparation.

Nephrotoxicity and Other Adverse Events: What Studies Report

Toxicity in the polymyxin literature is measured on the same clock as efficacy. The 2021 pharmacological review framed dose-limiting toxicity, particularly kidney injury, as one of the central challenges in rescuing these last-line agents for modern use (PMID 33627412). The 2019 clinical review of polymyxin B discussed safety monitoring as part of routine clinical use of the drug (PMID 31364080), and the 2019 meta-analysis of polymyxin use in patients pooled patient-level outcome data across published studies (PMID 31364077).

Because adverse-event monitoring typically runs concurrently with the treatment course, researchers reported harms over the same days-to-weeks interval in which clinical endpoints were assessed, as described in the clinical review of polymyxin B (PMID 31364080). No specific incidence figures are reproduced here, since the verified sources are reviews and syntheses rather than single-cohort safety reports.

Where Human Data Are Absent or Limited

• No outpatient or self-administered timeline exists. Systemic polymyxins are described in the literature as last-resort hospital antibiotics (PMID 35118938), and no verified source in this set described a community or self-directed course.
• Mechanistic kinetics are laboratory findings. Membrane-level activity was characterised in vitro and in mechanistic review, not measured in patients hour by hour (PMID 35118938).
• Combination questions remained unsettled. One 2019 review explicitly posed combination therapy as an open question (PMID 30974813), and a companion review addressed how combinations might be rationally selected (PMID 31364082).
• Haemoadsorption evidence is still evolving. A 2018 randomised trial anchored on 28-day mortality (PMID 30304428) was followed by a later phase 3 Bayesian randomised trial of polymyxin B haemoadsorption (PMID 41887242) and by network meta-analytic comparison of blood purification strategies (PMID 37470680).

How to Read a Polymyxin Timeline Without Over-Reading It

Three habits help. First, separate the measurement unit: hours for pharmacokinetics (PMID 33627412), days for clinical course (PMID 31364080), day 28 for sepsis mortality (PMID 30304428), and multi-week windows in the topical ear literature (PMID 31896168). Second, note the population: a trial restricted to septic shock with elevated endotoxin cannot speak to other settings (PMID 30304428). Third, remember that pooled estimates average across heterogeneous patients whose host responses differed by pathogen (PMID 41837287).

Nothing on this page forecasts an individual result. It reports what researchers measured and when. This page is educational only and is not medical advice; questions about antibiotics, infection or sepsis care belong with a licensed physician.

References

• Rescuing the Last-Line Polymyxins: Achievements and Challenges (Pharmacological Reviews, 2021)
• Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort (Microbiology, 2022)
• Clinical Use of Polymyxin B (Advances in Experimental Medicine and Biology, 2019)
• Meta-analysis of Polymyxin Use in Patients (Advances in Experimental Medicine and Biology, 2019)
• Polymyxins: To Combine or Not to Combine? (Antibiotics, 2019)
• Rational Combinations of Polymyxins with Other Antibiotics (Advances in Experimental Medicine and Biology, 2019)
• Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial (JAMA, 2018)
• Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial (The Lancet Respiratory Medicine, 2026)
• Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials (Critical Care Medicine, 2023)
• Pathogen characteristics are key determinants of distinct host response phenotypes of sepsis (The Journal of Clinical Investigation, 2026)
• Topical antibiotics for chronic suppurative otitis media (Cochrane Database of Systematic Reviews, 2020)